American Well Stock Earnings Reports

Amwell reported Q1 FY2026 results showing continued progress toward profitability and strategic consolidation around a unified platform for payers, providers and government customers. Key financials: total revenue of $54.9M (down ~18% YoY) with subscription revenue representing 53% of total (subscription $24.9M); AMG visit revenue $28.9M (up ~9% YoY) and ~382K AMG paid visits; total platform visits ~1.0M (down ~19% YoY) driven by portfolio changes. Gross profit was $28M (51% gross margin). Operating expenses fell ~31% YoY to $45.4M, and adjusted EBITDA loss narrowed to $3.1M (vs. $12.2M loss prior year). Cash and investments ended the quarter at ~$179–182M with zero debt and burn ~ $3.1M for the quarter. Management reiterated full-year revenue guidance of $195–205M and tightened adjusted EBITDA loss guidance to $(16)–$(12)M, and reiterated a path to positive operating cash flow in Q4 2026. Commercial and government traction: Elevance Health renewed for three years; Defense Health Agency (DHA) deployment is live globally and a renewal/possible expansion (including behavioral health) is expected in mid-2026, representing a material portion of platform value. Management emphasized growing pipeline (Mark called it a multiple of last year, qualitatively triple-digit growth), stronger renewal/retention than budgeted, and a strategic focus on selling a unified, AI-ready infrastructure that enables customers to run, measure and optimize AI-driven clinical programs. Key strategic points: platform-as-infrastructure positioning (Amwell as the governed environment for agentic AI), unified data/attribution as a sustainable advantage, shift in mix toward higher-margin SaaS and clinical programs (virtual primary care and other higher-acuity services), and continued cost discipline from 2025 operational changes.